Merck Licenses CRISPR Gene-Editing Technology to Evotec
License to accelerate research, enable testing and development of new drugs
13-Nov-2019 -
Merck announced that it has signed a license agreement providing Evotec SE access to Merck’s foundational CRISPR intellectual property. Evotec, an international biotechnology company headquartered in Hamburg, Germany, will use Merck’s CRISPR genome-editing technology to create edited cell lines ...
CRISPR
drug development
genome editing
+1